- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Lipitor may be the first statin to switch to OTC
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
NEW YORK — The Food and Drug Administration has declined to approve an investigative painkiller made by Pfizer, the drug maker said Friday.
The FDA issued a complete response letter for Remoxy (oxycodone) extended-release capsules, which Pfizer is developing under a partnership with Pain Therapeutics. Pain Therapeutics originally developed the drug using Durect’s Oradur technology, which is designed to prevent tampering by drug abusers, in collaboration with King Pharmaceuticals. Pfizer took control of development of the drug when it acquired King in February.
The FDA issues a complete response letter when it has finished reviewing a regulatory application for a drug, but remaining questions preclude final approval.